OTC and ornithine carbamoyltransferase deficiency: Mortality during the presenting episode is about 40% for neonatal‐onset ornithine transcarbamylase (OTC) deficiency [32, 36, 38] and 8%–10% for later onset OTC deficiency [36, 38].